| Title |
Clinical development of mTOR inhibitors in breast cancer
|
|---|---|
| Published in |
Breast Cancer Research, February 2014
|
| DOI | 10.1186/bcr3618 |
| Pubmed ID | |
| Authors |
Cecile Vicier, Maria Vittoria Dieci, Monica Arnedos, Suzette Delaloge, Patrice Viens, Fabrice Andre |
| Abstract |
The mammalian target of rapamycin (mTOR) pathway is a central pathway that regulates mRNA translation, protein synthesis, glucose metabolism, lipid synthesis and autophagy, and is involved in malignant transformation. Several randomized trials have shown that the use of mTOR inhibitors could improve patient outcome with hormone receptor-positive or human epidermal growth factor receptor-2-positive breast cancer. This review analyzes new perspectives from these trials. Preclinical studies have suggested that the mTOR pathway may play a role in the resistance to hormone therapy, trastuzumab and chemotherapy for breast cancer. This concept has been tested in clinical trials for neoadjuvant treatment and for metastatic breast cancer patients. Also, much effort has gone into the identification of biomarkers that will allow for more precise stratification of patients. Findings from these studies will provide indispensable tools for the design of future clinical trials and identify new perspectives and challenges for researchers and clinicians. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Italy | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Scientists | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 96 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Japan | 1 | 1% |
| United Kingdom | 1 | 1% |
| Ecuador | 1 | 1% |
| Germany | 1 | 1% |
| Unknown | 92 | 96% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 23 | 24% |
| Student > Ph. D. Student | 13 | 14% |
| Student > Master | 13 | 14% |
| Other | 8 | 8% |
| Student > Bachelor | 8 | 8% |
| Other | 23 | 24% |
| Unknown | 8 | 8% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 33 | 34% |
| Agricultural and Biological Sciences | 22 | 23% |
| Biochemistry, Genetics and Molecular Biology | 16 | 17% |
| Chemistry | 4 | 4% |
| Pharmacology, Toxicology and Pharmaceutical Science | 3 | 3% |
| Other | 9 | 9% |
| Unknown | 9 | 9% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 14 September 2014.
All research outputs
#20,656,161
of 25,373,627 outputs
Outputs from Breast Cancer Research
#1,705
of 2,052 outputs
Outputs of similar age
#176,615
of 238,199 outputs
Outputs of similar age from Breast Cancer Research
#21
of 29 outputs
Altmetric has tracked 25,373,627 research outputs across all sources so far. This one is in the 10th percentile – i.e., 10% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,052 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 12.2. This one is in the 8th percentile – i.e., 8% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 238,199 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 12th percentile – i.e., 12% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 29 others from the same source and published within six weeks on either side of this one. This one is in the 13th percentile – i.e., 13% of its contemporaries scored the same or lower than it.